Gastric Cancer

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

By

Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

By

A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

By

XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

By

Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.

Bursectomy Does Not Improve Survival in Gastric Cancer

Bursectomy Does Not Improve Survival in Gastric Cancer

By

Researchers randomly assigned 1204 patients with gastric adenocarcinoma to undergo omentectomy only or bursectomy.

Gastric Cancer: Postoperative Chemoradiotherapy Does Not Improve OS vs Chemotherapy

Gastric Cancer: Postoperative Chemoradiotherapy Does Not Improve OS vs Chemotherapy

By

Researchers randomly assigned 788 patients to receive postoperative chemotherapy or chemoradiotherapy.

Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy

Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy

By

Researchers identified 4 classifier genes relevant to gastric cancer in 307 patients in an internal cohort.

Phase 2 Study of Surgical Resection and HIPEC for Gastric Cancer

Phase 2 Study of Surgical Resection and HIPEC for Gastric Cancer

By

Researchers are investigating the efficacy of surgical resection plus HIPEC for improving survival outcomes among patients with gastric cancer.

Phase 2 Study of Chemoradiotherapy Alone or With Surgery for Esophageal and Gastric Cancer

Phase 2 Study of Chemoradiotherapy Alone or With Surgery for Esophageal and Gastric Cancer

By

Researchers are evaluating the safety and efficacy of additional chemotherapy and radiation, alone or with surgery, among patients with esophageal or gastric cancer.

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

By

Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.

Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

By

Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

By

In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.

Phase 2 Trial of Nab-paclitaxel Plus FOLFOX As First-line Therapy for Gastric Cancer

Phase 2 Trial of Nab-paclitaxel Plus FOLFOX As First-line Therapy for Gastric Cancer

By

Researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel as a first-line therapy for patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.

Phase 1b/2 Trial of PLX9486 for Patients With A Gastrointestinal Stromal Tumor

Phase 1b/2 Trial of PLX9486 for Patients With A Gastrointestinal Stromal Tumor

By

Researchers are evaluating the safety and efficacy of PLX9486, a TKI of c-Kit, in combination with pexidartinib (PLX3397) and sunitinib among patients with GIST.

Stage 2 Trial of Pembrolizumab Plus Standard Chemotherapy for Gastric Cancers

Stage 2 Trial of Pembrolizumab Plus Standard Chemotherapy for Gastric Cancers

By

Researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal junction.

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab Active in Advanced Gastric Cancer

By

Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

By

Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.

Neoadjuvant Chemotherapy Followed by Surgery for Metastatic Gastric Cancer

Neoadjuvant Chemotherapy Followed by Surgery for Metastatic Gastric Cancer

By

Neoadjuvant FLOT followed by surgery improves outcomes among patients with gastric or gastroesophageal junction cancer.

Phase 2 Study of Andecaliximab and Nivolumab for Gastroesophageal Junction or Gastric Cancer

Phase 2 Study of Andecaliximab and Nivolumab for Gastroesophageal Junction or Gastric Cancer

By

For this phase 2 trial, researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone.

Gastroesophageal Cancer: High MSI Associated With No Benefit From Perioperative Chemo

Gastroesophageal Cancer: High MSI Associated With No Benefit From Perioperative Chemo

By

Patients with operable gastroesophageal cancer with high microsatellite instability did not derive benefit from perioperative chemotherapy.

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

By

GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

By

Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

By

The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

By

For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.

Surgical Palliation for Gastric Outlet Obstruction

Surgical Palliation for Gastric Outlet Obstruction

By

Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.

Watch-and-Wait Safe for Patients With Rectal Cancer

Watch-and-Wait Safe for Patients With Rectal Cancer

By

Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.

FDA Accepts Biologics License Application for Proposed Biosimilar Trastuzumab

FDA Accepts Biologics License Application for Proposed Biosimilar Trastuzumab

By

The FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401O.

Nivolumab Improves Overall Survival in Advanced Gastric Cancer

Nivolumab Improves Overall Survival in Advanced Gastric Cancer

By

Nivolumab (Opdivo) improved overall survival compared with placebo among patients with unresectable advanced or recurrent gastric cancer.

BLA for Proposed Trastuzumab Biosimilar Submitted to FDA

BLA for Proposed Trastuzumab Biosimilar Submitted to FDA

By

Mylan has submitted a biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, to the FDA.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs